AtriCure Inc. (NASDAQ:ATRC) CFO M. Andrew Wade sold 704 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $30.00, for a total transaction of $21,120.00. Following the sale, the chief financial officer now owns 166,120 shares in the company, valued at $4,983,600. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
M. Andrew Wade also recently made the following trade(s):
- On Tuesday, April 30th, M. Andrew Wade sold 9,850 shares of AtriCure stock. The stock was sold at an average price of $30.00, for a total value of $295,500.00.
Shares of NASDAQ ATRC traded up $0.74 on Monday, reaching $30.58. 183,643 shares of the company traded hands, compared to its average volume of 223,677. AtriCure Inc. has a fifty-two week low of $26.11 and a fifty-two week high of $36.49. The firm’s 50 day moving average is $29.65. The company has a quick ratio of 3.69, a current ratio of 4.37 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $1.18 billion, a PE ratio of -32.53 and a beta of 0.27.
Several research analysts have recently issued reports on ATRC shares. BTIG Research raised AtriCure from a “neutral” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Tuesday, April 2nd. Needham & Company LLC reissued a “buy” rating and issued a $39.00 target price on shares of AtriCure in a research note on Thursday, March 28th. Northland Securities reissued a “buy” rating on shares of AtriCure in a research note on Friday, April 26th. ValuEngine downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 19th. Finally, BidaskClub raised shares of AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, May 18th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $36.67.
Large investors have recently modified their holdings of the company. Tibra Equities Europe Ltd purchased a new stake in shares of AtriCure during the 1st quarter worth about $370,000. D. E. Shaw & Co. Inc. boosted its holdings in AtriCure by 55.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 270,915 shares of the medical device company’s stock worth $8,290,000 after acquiring an additional 96,176 shares during the period. Robeco Institutional Asset Management B.V. purchased a new position in AtriCure in the 4th quarter worth approximately $190,000. American International Group Inc. boosted its holdings in AtriCure by 9.1% in the 4th quarter. American International Group Inc. now owns 24,272 shares of the medical device company’s stock worth $743,000 after acquiring an additional 2,027 shares during the period. Finally, Northern Trust Corp boosted its holdings in AtriCure by 9.1% in the 4th quarter. Northern Trust Corp now owns 489,179 shares of the medical device company’s stock worth $14,969,000 after acquiring an additional 40,760 shares during the period. Institutional investors and hedge funds own 89.28% of the company’s stock.
AtriCure Company Profile
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.